

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Health Technology Evaluation**

**Equality impact assessment – Scoping**

**Decitabine–cedazuridine with venetoclax for treating acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The company consultation response highlighted that:

- People in remote areas may struggle to attend hospital to receive treatments – an oral treatment will improve treatment access.
- Most people with AML are older in age.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Issues related to differences in prevalence or incidence of a disease cannot be addressed in a technology appraisal.

Access to treatment is an implementation issue and cannot be addressed in technology appraisal guidance.

If relevant, the potential equality issues raised will be considered by the committee during decision making.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

**Approved by Principal Technical Adviser (name):** Lizzie

Walker.....

**Date:** 01/04/2026